Abbott beats profit estimates on medical devices demand, shares fall on forecast

Abbott Laboratories reported Q2 adjusted EPS of $1.26 and revenue of $11.14 billion, both exceeding analyst estimates, driven by robust medical device sales, including a 21.4% increase in continuous glucose monitoring devices to $1.9 billion. Despite the strong Q2 performance, shares declined over 4% premarket after the company's Q3 earnings forecast of $1.28-$1.32 per share missed the $1.34 consensus. Abbott also announced plans for a new U.S. manufacturing facility in Georgia by 2028, complementing existing domestic expansions, aimed at bolstering its cardiovascular business and mitigating potential tariff impacts.

Analysis

Abbott Laboratories reported mixed second-quarter results, beating analyst estimates on profit and revenue but issuing a weaker-than-expected third-quarter forecast. The company posted an adjusted profit of $1.26 per share on revenue of $11.14 billion, surpassing respective estimates of $1.25 and $11.07 billion. This performance was anchored by the medical device business, which generated $5.37 billion in sales, driven by a significant 21.4% year-over-year increase in its continuous glucose monitoring device sales to $1.9 billion. This highlights strong underlying demand in a key growth segment. However, the positive results were overshadowed by the company's Q3 earnings guidance of $1.28-$1.32 per share, which fell short of the $1.34 consensus and triggered a premarket share decline of over 4%. Strategically, Abbott is moving to de-risk its supply chain by announcing a new U.S. manufacturing facility in Georgia by 2028, complementing other domestic projects to mitigate potential tariff impacts.

Key Decisions for Investors

• Investors should recognize the market's focus on the disappointing third-quarter earnings guidance, which is likely to create near-term price pressure on the stock despite the solid Q2 beat.
• The 21.4% growth in the continuous glucose monitoring segment confirms a powerful secular trend, suggesting that any price weakness could present an opportunity for long-term investors confident in the underlying business fundamentals.
• It is crucial to monitor management's commentary for the specific drivers behind the soft Q3 forecast and track the performance of competitors like Dexcom and Medtronic to differentiate between company-specific issues and broader industry trends.